AJP - Lung Cellular and Molecular Physiology, Vol 259, Issue 4 255-L261, Copyright © 1990 by American Physiological Society

ARTICLES

Cysteinyl leukotrienes enhance growth of human airway epithelial cells

G. D. Leikauf, H. E. Claesson, C. A. Doupnik, S. Hybbinette and R. C. Grafstrom
Department of Environmental Health, University of Cincinnati Medical Center, Ohio 45267-0182.

Epithelial inflammation may play an obligatory role in the pathogenesis of a number of chronic pulmonary diseases such as asthma or bronchitis and has been implicated during the promotion phase of multistage carcinogenesis. At sites of inflammation, bioactive lipid mediators are released and activate a wide range of pathophysiological responses including bronchospasm. Previous studies suggest that one class of inflammatory mediators, the eicosanoids, can also influence cell growth. Epithelial cell proliferation and hyperplasia are common sequelae to irritation and inflammation, and because the lung has a high capacity to produce eicosanoids, we investigated the effects of a group of these compounds, the cysteinyl leukotrienes, on growth of human airway epithelial cells. Leukotrienes were found to be mitogenic in a concentration-dependent manner and exhibit a structure-activity relationship, with leukotriene C4 being more potent than its sequential metabolites leukotriene D4 and E4. The potency of leukotriene C4 is striking, stimulating colony-forming efficiency in concentrations as low as 10 fM. These findings suggest a new physiological role for leukotrienes in the lung that links inflammation with epithelial cell proliferation.

This article has been cited by other articles:

				M. M. Choe, P. H. S. Sporn, and M. A. Swartz An in vitro airway wall model of remodeling Am J Physiol Lung Cell Mol Physiol, August 1, 2003; 285(2): L427 - L433. [Abstract] [Full Text] [PDF]

				U. Savla, H. J. Appel, P. H. S. Sporn, and C. M. Waters Prostaglandin E2 regulates wound closure in airway epithelium Am J Physiol Lung Cell Mol Physiol, March 1, 2001; 280(3): L421 - L431. [Abstract] [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				S. Ravasi, V. Capra, M. Mezzetti, S. Nicosia, and G. E. Rovati A Kinetic Binding Study to Evaluate the Pharmacological Profile of a Specific Leukotriene C4 Binding Site Not Coupled to Contraction in Human Lung Parenchyma Mol. Pharmacol., June 1, 2000; 57(6): 1182 - 1189. [Abstract] [Full Text]

				J. BOUSQUET, P. K. JEFFERY, W. W. BUSSE, M. JOHNSON, and A. M. VIGNOLA Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1720 - 1745. [Full Text]

				S. T. HOLGATE and A. P. SAMPSON Antileukotriene Therapy . Future Directions Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S147 - 153. [Full Text] [PDF]

				K. Takeyama, K. Dabbagh, H.-M. Lee, C. Agusti, J. A. Lausier, I. F. Ueki, K. M. Grattan, and J. A. Nadel Epidermal growth factor system regulates mucin production in airways PNAS, March 16, 1999; 96(6): 3081 - 3086. [Abstract] [Full Text] [PDF]